AVM
RAPP

Arch Venture Management’s Rapport Therapeutics RAPP Stock Holding History

Arch Venture Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155M Hold
3,728,738
– – 14.12% 3
2026
Q1 		$117M Hold
3,728,738
– – 17.23% 2
2025
Q4 		$113M Hold
3,728,738
– – 17.36% 3
2025
Q3 		$111M Hold
3,728,738
– – 22.49% 1
2025
Q2 		$42.4M Hold
3,728,738
– – 14.19% 4
2025
Q1 		$37.5M Hold
3,728,738
– – 18.21% 3
2024
Q4 		$66.1M Hold
3,728,738
– – 28.73% 2
2024
Q3 		$76.4M Hold
3,728,738
– – 29.31% 2
2024
Q2 		$86.7M Buy
+3,728,738
New +$86.3M 32.6% 2

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Arch Venture Management's RAPP Position: Q2 2026 in Review

Arch Venture Management held its Rapport Therapeutics (RAPP) position steady in Q2 2026 at 3,728,738 shares worth $155M. The position accounts for 14.12% of the portfolio, ranked #3.

Arch Venture Management first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Arch Venture Management held 3,728,738 shares of Rapport Therapeutics worth $155M as of Q2 2026.
  • Arch Venture Management left its Rapport Therapeutics share count unchanged in Q2 2026.
  • Rapport Therapeutics made up 14.12% of Arch Venture Management's portfolio in Q2 2026, its #3 holding.
  • Arch Venture Management first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Arch Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.